Commentary on Ho et al. (2019): Managing people with HIV and drug problems is complex and multi-faceted
International literature reviews can provide important insights into global drug use and HIV infection treatment. Management of HIV-infected individuals with coexisting drug problems requires a range of services, including medical prescribing, but crucially these must be engaged, sympathetic and supportive of those people who are estranged and marginalized. This paper by Ho et al. [1] is important, because it gives us an insight into the complexity of managing people who inject drugs and the impact and influence of life-style, poverty, adversity and the current limitations of public health policy in many, if not most, countries. The importance of life-style and economic stresses and the consequent need to accommodate difficulties in these areas should not need to be highlighted, but they are clearly an essential, and frequently missed, part of public health policy and clinical practice when delivering critical treatment to people constrained by drug use difficulties.
The paper also draws attention to how people who use drugs are perceived and supported. In doing so, it strikes at the heart of many challenges for service delivery [1] . These cluster around drug policy, stigma inhibiting change, variations between administrations, multi-drug use complicating risks, comorbid mental health problems and the dynamics between identifying the evidence supporting treatment and translating this into actions in affected communities.
An additional message that we might extrapolate is the importance of people who inject drugs (PWID) for the impact of the world-wide HIV/AIDS epidemic, which is now driven by drug injecting in many countries (especially in Asia and increasingly in Africa) [2] . Adherence to anti-retroviral therapy is constrained, not surprisingly, by ongoing drug use and various other factors that alert us to the focused attention needed to provide quality treatment services delivered with compassion and sufficient resources.
The lessons of the last 30 years are that administrations experiencing drug use epidemics and managing and preventing HIValways seem to struggle to implement effective interventions such as medically assisted treatment (MAT) and needle and syringe availability. A binary approach between recovery/abstinence and harm reduction is over-simplistic, and treatment services need to be much more nuanced, personal and inclusive [3] . Despite an extensively researched and widely published literature drawing attention to the benefits of engagement and retention in MAT programmes [4, 5] , political decision-making and consensus always seem to lag behind or, in many cases, obstruct clinical practice.
Crises generate change, however [6] , and there are many examples of drug problems having dramatic effects as unexpected problems require new approaches. The United Kingdom changed drug policy in the 1980s in response to HIV infection and, more recently, the United States and Canada have had to make difficult political decisions in the wake of an epidemic of fentanyl and oxycodone use and overdose [7, 8] . Indeed, the rising number of drugrelated deaths in many countries is currently a major driver of drug policy change around the world, as it affects life expectancy and challenges conservative policy [9, 10] . The changes made need to destigmatize people who use drugs and to reduce the barriers to treatment access by increasing the targeted funding to support treatment services, encouraging research and inclusive practice.
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